Biomedicine & Pharmacotherapy (Sep 2022)

Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases

  • Hongyu Chen,
  • Junmin Wang,
  • Caiyun Zhang,
  • Peilun Ding,
  • Shuxia Tian,
  • Junming Chen,
  • Guang Ji,
  • Tao Wu

Journal volume & issue
Vol. 153
p. 113341

Abstract

Read online

Sphingosine 1-phosphate receptor (S1PR), as a kind of G protein-coupled receptor, has five subtypes, including S1PR1, S1PR2, S1PR3, S1PR4, and S1PR5. Sphingosine 1-phosphate receptor (S1P) and S1PR regulate the trafficking of neutrophils and some cells, which has great effects on immune systems, lung tissue, and liver tissue. Presently, many related reports have proved that S1PR has a strong effect on the migration of lymphocytes, tumor cells, neutrophils, and many other cells via the regulation of signals, pathways, and enzymes. In this way, S1PR can regulate the relative response of the organism. Thus, S1PR has become a possible target for the treatment of autoimmune diseases, pulmonary disease, liver disease, and cancer. In this review, we mainly focus on the research of the S1PR for the new therapeutic directions of different diseases and is expected to assist support in the clinic and drug use.

Keywords